Ascentage Net Receivables from 2010 to 2026
| AAPG Stock | 26.48 0.28 1.07% |
Net Receivables | First Reported 2017-06-30 | Previous Quarter 99.1 M | Current Value 78.4 M | Quarterly Volatility 224.8 M |
Check Ascentage Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Ascentage Pharma's main balance sheet or income statement drivers, such as Depreciation And Amortization of 112.5 M, Interest Expense of 41.4 M or Selling General Administrative of 117.8 M, as well as many indicators such as Price To Sales Ratio of 42.69, Dividend Yield of 0.0 or PTB Ratio of 137. Ascentage financial statements analysis is a perfect complement when working with Ascentage Pharma Valuation or Volatility modules.
Ascentage | Net Receivables | Build AI portfolio with Ascentage Stock |
Latest Ascentage Pharma's Net Receivables Growth Pattern
Below is the plot of the Net Receivables of Ascentage Pharma Group over the last few years. It is Ascentage Pharma's Net Receivables historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Ascentage Pharma's overall financial position and show how it may be relating to other accounts over time.
| Net Receivables | 10 Years Trend |
|
Net Receivables |
| Timeline |
Ascentage Net Receivables Regression Statistics
| Arithmetic Mean | 40,356,762 | |
| Geometric Mean | 15,016,956 | |
| Coefficient Of Variation | 129.14 | |
| Mean Deviation | 43,488,986 | |
| Median | 8,308,000 | |
| Standard Deviation | 52,115,425 | |
| Sample Variance | 2716T | |
| Range | 163.1M | |
| R-Value | 0.78 | |
| Mean Square Error | 1139.2T | |
| R-Squared | 0.61 | |
| Significance | 0.0002 | |
| Slope | 8,039,055 | |
| Total Sum of Squares | 43456.3T |
Ascentage Net Receivables History
About Ascentage Pharma Financial Statements
Ascentage Pharma stakeholders use historical fundamental indicators, such as Ascentage Pharma's Net Receivables, to determine how well the company is positioned to perform in the future. Although Ascentage Pharma investors may analyze each financial statement separately, they are all interrelated. For example, changes in Ascentage Pharma's assets and liabilities are reflected in the revenues and expenses on Ascentage Pharma's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Ascentage Pharma Group. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Net Receivables | 113.9 M | 119.6 M |
Currently Active Assets on Macroaxis
When determining whether Ascentage Pharma is a strong investment it is important to analyze Ascentage Pharma's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Ascentage Pharma's future performance. For an informed investment choice regarding Ascentage Stock, refer to the following important reports:Check out the analysis of Ascentage Pharma Correlation against competitors. You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ascentage Pharma. If investors know Ascentage will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ascentage Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.08) | Revenue Per Share | Quarterly Revenue Growth (0.72) | Return On Assets | Return On Equity |
The market value of Ascentage Pharma is measured differently than its book value, which is the value of Ascentage that is recorded on the company's balance sheet. Investors also form their own opinion of Ascentage Pharma's value that differs from its market value or its book value, called intrinsic value, which is Ascentage Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ascentage Pharma's market value can be influenced by many factors that don't directly affect Ascentage Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ascentage Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Ascentage Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ascentage Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.